Planta Med 2022; 88(14): 1293-1298
DOI: 10.1055/a-1728-4963
Biological and Pharmacological Activity
Original Papers

Cytochalasan Alkaloids as TRAIL Sensitizers from an Endophytic Fungus Chaetomium sp.

Ying Gao
1   School of Pharmacy, Tongji Medical College of Huazhong University of Science and Technology, Hubei Key Laboratory of Natural Medicinal Chemistry and Resource Evaluation, Wuhan, Peopleʼs Republic of China
,
Ruihua Mao
1   School of Pharmacy, Tongji Medical College of Huazhong University of Science and Technology, Hubei Key Laboratory of Natural Medicinal Chemistry and Resource Evaluation, Wuhan, Peopleʼs Republic of China
2   Department of Pharmacy, Tongji Hospital Affiliated Huazhong University of Science and Technology, Wuhan, Peopleʼs Republic of China
,
Ye Liu
3   Key Laboratory of Plant Germplasm Enhancement and Specialty Agriculture, Wuhan Botanical Garden, Chinese Academy of Sciences, Wuhan, Peopleʼs Republic of China
,
Ming Zhou
3   Key Laboratory of Plant Germplasm Enhancement and Specialty Agriculture, Wuhan Botanical Garden, Chinese Academy of Sciences, Wuhan, Peopleʼs Republic of China
,
1   School of Pharmacy, Tongji Medical College of Huazhong University of Science and Technology, Hubei Key Laboratory of Natural Medicinal Chemistry and Resource Evaluation, Wuhan, Peopleʼs Republic of China
› Author Affiliations

Supported by: National Natural Science Foundation of China Nos. 31770380 and 22077041 Supported by: Health Commission of Hubei Province No. ZY2021M004
Preview

Abstract

Two new cytochalasans with a rare 6/6/5/5/7 pentacyclic ring system, named chaetoconvosins C−D (12), together with two known congeners (34), were isolated from the fermentation of an endophytic fungus, Chaetomium sp. SG-01, harbored in the fibrous roots of Schisandra glaucescens Diels. Their structures including the absolute configuration were elucidated by extensive spectroscopic (HRESIMS, NMR, and ECD) and X-ray crystallographic analyses. The TRAIL-resistance-overcoming activity of 14 in a TRAIL-resistant HT29 colorectal cancer cell line was evaluated, which revealed that co-treatment of 14 at 50 µM with TRAIL (150 ng/mL) reduced the HT29 cell viability by 19.0%, 24.1%, 17.9%, and 15.5%, respectively, compared to treatment with 14 alone.

Supporting Information



Publication History

Received: 17 September 2021

Accepted after revision: 28 December 2021

Accepted Manuscript online:
28 December 2021

Article published online:
28 February 2022

© 2022. Thieme. All rights reserved.

Georg Thieme Verlag KG
Rüdigerstraße 14, 70469 Stuttgart, Germany